Selective, Hsp90 competitive inhibitor (Ki = 1.7 nM). Displays no significant activity at a range of ATP-binding kinases or Na+K+ ATPase. Induces degradation of HER-2 in vitro (EC50 = 38 nM in MCF-7 cells). Inhibits growth and promotes cell death in a variety of human tumor cells. Orally bioavailable.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 318.76. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.14 mL||15.69 mL||31.37 mL|
|5 mM||0.63 mL||3.14 mL||6.27 mL|
|10 mM||0.31 mL||1.57 mL||3.14 mL|
|50 mM||0.06 mL||0.31 mL||0.63 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Lundgren et al (2009) BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol.Cancer Ther. 8 921 PMID: 19372565
Yin et al (2010) BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int.J.Cancer 126 1216 PMID: 19662650
If you know of a relevant reference for BIIB 021, please let us know.
View Related Products by Product Action
Keywords: BIIB021 heat shock proteins 90 hsp90 inhibitors chaperones HER-2 antitumor antitumour CNF2024 inhibits orally bioavailable potent selective CNF 2024 Hsp90
Citations for BIIB 021
Citations are publications that use Tocris products.
Currently there are no citations for BIIB 021. Do you know of a great paper that uses BIIB 021 from Tocris? If so please let us know.
Literature in this Area
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.